ESMO 2025

Reassuring data on pregnancy for young EBC patients

Refining the standard treatments for early breast…

Rethinking dosing in TNBC

Confirmative OS data on CDK4/6 inibitors for pts with…

Great update for young women

T-DXd in high-risk patients in the postneoadjuvant…

T-DXd right from the start – in a neoadjuvant situation…

New insights into PROTAC SERD vepdegestrant

monarchE OS

Adjuvant data with CDK4/6 inhibitors in HR+ breast…

Financial toxicity

POSITIVE trial - update

T-DXd neoadjuvant improves pCR

Exciting news for young patients who want to get…

CDK4/6 inhibitors – confirmed effect

Individual consultation remains important

Optimizing G-CSF administration helps reducing side…

Ki67 after preoperative chemotherapy - a new strong…

Optimal timepoint of G-CSF administration after…

OS-benefit with abemaciclib

A first step into a great story

First time OS - confirming clinical practice

Durvalumab improves OS in TNBC

monarchE OS

La primera terapia neoadyuvante reduce la quimioterapia…

Studio POSITIVE - aggiornamento

Momento óptimo para la administración de G-CSF después…

Un primer paso hacia una gran historia

Prima valutazione della OS: conferma della pratica…

Future perspectives for firstline therapy

ADCs in mBC - the story is not finished

Future perspectives on TNBC therapy

Survival data from SONIA

ADC, the first

Should this drug be available outside of China?

Another good option for patients with mTNBC

Transforming TNBC

Changing the paradigm of treatment in 1L of TNBC

Which ADC in 1L for metastatic TNBC

ADCs are coming for first line TNBC

Reforming destiny

Gedatolisib in patients with PI3K wild type HR+ mBC

Combination matters

Stronger together

TROP2 ADC, the second

TROP2 number 3

Breakthroughs for high-risk patients

Meeting the unmet need in advanced TNBC not eligible…

Più forti insieme

La combinazione conta

Nowa szansa dla chorych na zaawansowanego, potrójnie…

Cambiando el paradigma del tratamiento en la primera…

Gedatolisib chez les patients atteints d'un cancer du…

Otra buena opción para pacientes con mTNBC

Gli ADC si fanno strada nella prima linea del TNBC

Positionnement plus précoce des ADCs de troisième…

Evolving immunotherapy approaches in locally advanced…

Immunotherapy and biomarkers in resectable NSCLC:…

Neoadjuvant chemo/immuno - the bridge to make…

New chances for locally advanced NSCLC

ALEX: Long-term OS benefit with Alectinib in ALK+ NSCLC

New targeted therapies in HER2-mutated NSCLC

Therapy sequencing after EGFR-TKI progression: insights…

FLAURA2: OS outcomes in poor-prognosis EGFRm NSCLC with…

The return of antiangiogenic strategy in squamous NSCLC

Local therapy in addition to osimertinib 1st line in…

New kid on the block for EGFRm

Sac-TMT now also available for NSCLC

Update for pts with BRAF mutation

Two frontline HER2-options - is this the future?

sac-TMT a new SOC

Anti-TROP-2 ADCS - new data in EGFRm NSCLC

NorthStar - new navigation principle

Treat your BRAF-patients in 1L

HER2 altered - small population, many options

Sac-TMT - a potential new option for EGFRm NSCLC…

Local ablative therapy in EGFR-mutated NSCLC

Alectinib remains a potential SOC

New options after EGFR-TKI failure

The added value of radiotherapy in EGFR mutated NSCLC

New treatment options for HER2-mutation positive NSCLC

Save and effective - Ivonescimab in HARMONi-6

EGFR exon 20 - What does the future hold?

Two is better than one

New chances for locally advanced NSCLC

Eradication of all disease - is this the true north?

Is chemo-IO an option if you want a rapid response in…

New prospect for squamous tumors

Ivonescimab in NSCLC - a new SOC?

Is this the end for pembrolizumab?

Sac - TMT - une nouvelle option potentielle pour le…

È la fine per Pembrolizumab?

New kid on the block for EGFRm

Le retour de la stratégie antiangiogénique dans le…

Due è meglio di uno

Nuevas perspectivas para los tumores escamosos

De toegevoegde waarde van radiotherapie bij…

Prognostic role of exosomes in stage IIIA(N2) NSCLC…

Long-term outcomes with tepotinib in METex14 skipping…

Will tarlatamab improve 1st line treatment for…

DLL3 targeting drugs moving to frontline therapy

T-cell engager in 1st line SCLC

Dramatic improvement of PFS in 1L treatment

Tarlatamab combination in 1st line SCLC

Zal tarlatamab de eerstelijnsbehandeling van…

Doblando la gravedad del SCLC

A new class of drugs in Mesothelioma treatment

A step in the right direction

Adding to the adjuvant RCC story - how do we move…

Kidney cancer advances from ESMO

The dawn of molecular imaging in renal cell carcinoma

LenCabo - early activity, but we need more data

Further intensification of therapy with potential…

Therapy-relevant aspects for first-line treatment of…

Relevance of CPI neoadjuvant and adjuvant

Adjuvans in high risk RCC after surgery

More evidence in second-line treatment for metastatic…

MIBC: Is ctDNA monitoring ready for daily practice?

NMIBC: Making the right choice for high risk patients!

UTUC: Impressive PFS und OS Benefit with Disitamab…

Perioperative and adjuvant standards for MIBC

Bladder cancer highlights from ESMO 2025

De-escalation promotes a better QoL while maintaining…

New benchmark for MIBC and platinum-unsuitable patients

A highly selective FGFR3 inhibitor for first-line…

Neoadjuvant HER2-targeted therapy for kidney-sparing…

Adding checkpoint inhibitor in high risk NMIBC shows…

Dose modifications, new combinations, new substances in…

New options for neoadjuvant therapy in MIBC

ADC Enfortumab vedotin + Pembrolizumab in MIBC

When precision matters, the case of ctDNA in MIBC

Setting the bar even higher in MIBC

Negative, but important data to discuss

Is ICI to BCG suitable for NMIBC?

A well-tolerated and effective new neoadjuvant concept…

Neoadjuvant combination of local and systemic therapy…

Too early for primetime

A newcomer in advanced urothelial cancer

Better QoL for patients with metastatic bladder cancer

The ADC story continues

Un recién llegado en el cáncer urotelial avanzado

Cuando la precisión importa: el caso de ctDNA en MIBC

Κύρια σημεία για τον καρκίνο της ουροδόχου κύστης από…

Elevando aún más el estándar en MIBC

A Game-Changer for Early Relapse?

Example for biomarker guided precision medicine in…

Changed chemo-regimen leads to less toxicity in mHSPC

PSMAddition - Is it time for more?

New docetaxel regimen in combination with darolutamide…

Practice-changing data for mHSPC

Triplet regimen with reduced chemotherapy – fewer side…

Docetaxel vs. Lutetium in chemosensitive mCRPC

Final OS results for EMBARK

OS-benefit in BCR

The role of lutetium in mHSPC – is its use clinically…

Ändrad kemoterapiregim leder till mindre toxicitet vid…

Exempel på biomarkörstyrd precisionsmedicin vid…

Social Listening